- Home
- BGI vs QNRX Comparison
BGI vs QNRX Comparison
Compare BGI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGI | QNRX |
|---|---|---|
| Founded | 1879 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 11.6M |
| IPO Year | 2002 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BGI | QNRX |
|---|---|---|
| Price | $0.63 | $5.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.5K | ★ 22.7K |
| Earning Date | 12-05-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $4.55 |
| 52 Week High | $1.57 | $41.80 |
Technical Indicators
Market Signals| Indicator | BGI | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 34.28 |
| Support Level | N/A | N/A |
| Resistance Level | $0.71 | $6.84 |
| Average True Range (ATR) | 0.03 | 0.44 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 20.02 | 20.56 |
Price Performance
Historical ComparisonAbout BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.